BACKGROUND: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibility in a multicenter study that includes both academic and community-based practices, a phase II study of this regimen was conducted by SWOG. PATIENTS AND METHODS: Forty-nine patients with advanced stage, previously untreated MCL were eligible. The median age was 57.4 years (35-69.8 years). RESULTS: Nineteen patients (39%) did not complete the full scheduled course of treatment due to toxicity. There was one treatment-related death and two cases of secondary myelodysplastic syndrome (MDS). There were 10 episodes of grade 3 febrile neutropenia, 19 episodes of grade 3 and 1 episode of grade 4 infection. With a median follow-up of 4.8 years, the median progression-free survival was 4.8 years (5.5 years for those ≤ 65 years) and the median overall survival (OS) was 6.8 years. CONCLUSIONS: Although this regimen is toxic, it is active for patients ≤ 65 years of age and can be given both at academic centers and in experienced community centers.
BACKGROUND:Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibility in a multicenter study that includes both academic and community-based practices, a phase II study of this regimen was conducted by SWOG. PATIENTS AND METHODS: Forty-nine patients with advanced stage, previously untreated MCL were eligible. The median age was 57.4 years (35-69.8 years). RESULTS: Nineteen patients (39%) did not complete the full scheduled course of treatment due to toxicity. There was one treatment-related death and two cases of secondary myelodysplastic syndrome (MDS). There were 10 episodes of grade 3 febrile neutropenia, 19 episodes of grade 3 and 1 episode of grade 4 infection. With a median follow-up of 4.8 years, the median progression-free survival was 4.8 years (5.5 years for those ≤ 65 years) and the median overall survival (OS) was 6.8 years. CONCLUSIONS: Although this regimen is toxic, it is active for patients ≤ 65 years of age and can be given both at academic centers and in experienced community centers.
Authors: N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield Journal: Histopathology Date: 2000-01 Impact factor: 5.087
Authors: Stephen M Ansell; Hui Tang; Paul J Kurtin; Patricia A Koenig; David J Inwards; Keith Shah; Steven C Ziesmer; Andrew L Feldman; Radha Rao; Mamta Gupta; Charles Erlichman; Thomas E Witzig Journal: Lancet Oncol Date: 2011-04 Impact factor: 41.316
Authors: Jorge E Romaguera; Luis E Fayad; Lei Feng; Kimberly Hartig; Pamela Weaver; Maria Alma Rodriguez; Fredrick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Fernando Cabanillas; Hagop Kantarjian; Larry Kwak; Michael Wang Journal: Br J Haematol Date: 2010-05-26 Impact factor: 6.998
Authors: Jorge E Romaguera; Luis Fayad; Maria A Rodriguez; Kristine R Broglio; Frederick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Andreas H Sarris; Nam H Dang; Michael Wang; Virginia Beasley; L Jeffrey Medeiros; Ruth L Katz; Harish Gagneja; Barry I Samuels; Terry L Smith; Fernando F Cabanillas Journal: J Clin Oncol Date: 2005-09-06 Impact factor: 44.544
Authors: Georg Lenz; Martin Dreyling; Eva Hoster; Bernhard Wörmann; Ulrich Dührsen; Bernd Metzner; Hartmut Eimermacher; Andreas Neubauer; Hannes Wandt; Hjalmar Steinhauer; Sonja Martin; Else Heidemann; Ali Aldaoud; Reza Parwaresch; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann Journal: J Clin Oncol Date: 2005-01-24 Impact factor: 44.544
Authors: F Lefrère; A Delmer; F Suzan; V Levy; C Belanger; M Djabarri; B Arnulf; G Damaj; N Maillard; V Ribrag; M Janvier; C Sebban; R-O Casasnovas; R Bouabdallah; F Dreyfus; V Verkarre; E Delabesse; F Valensi; E McIntyre; N Brousse; B Varet; O Hermine Journal: Leukemia Date: 2002-04 Impact factor: 11.528
Authors: Christian H Geisler; Arne Kolstad; Anna Laurell; Niels S Andersen; Lone B Pedersen; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Måns Akerman; Mats Ehinger; Christer Sundström; Ruth Langholm; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen Journal: Blood Date: 2008-07-14 Impact factor: 22.113
Authors: Eva Hoster; Martin Dreyling; Wolfram Klapper; Christian Gisselbrecht; Achiel van Hoof; Hanneke C Kluin-Nelemans; Michael Pfreundschuh; Marcel Reiser; Bernd Metzner; Hermann Einsele; Norma Peter; Wolfram Jung; Bernhard Wörmann; Wolf-Dieter Ludwig; Ulrich Dührsen; Hartmut Eimermacher; Hannes Wandt; Joerg Hasford; Wolfgang Hiddemann; Michael Unterhalt Journal: Blood Date: 2007-10-25 Impact factor: 22.113
Authors: Stephen E Spurgeon; Brian G Till; Peter Martin; Andre H Goy; Martin P Dreyling; Ajay K Gopal; Michael LeBlanc; John P Leonard; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; Brad S Kahl; Mitchell R Smith Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Julie E Chang; Hailun Li; Mitchell R Smith; Randy D Gascoyne; Elisabeth M Paietta; David T Yang; Ranjana H Advani; Sandra J Horning; Brad S Kahl Journal: Blood Date: 2014-01-23 Impact factor: 22.113
Authors: Matthew G Mei; Thai M Cao; Lu Chen; Joo Y Song; Tanya Siddiqi; Ji-Lian Cai; Leonardo T Farol; Monzr M Al Malki; Amandeep Salhotra; Ibrahim Aldoss; Joycelynne Palmer; Alex F Herrera; Jasmine Zain; Leslie L Popplewell; Robert W Chen; Steven T Rosen; Stephen J Forman; Larry Kwak; Auayporn P Nademanee; Lihua E Budde Journal: Biol Blood Marrow Transplant Date: 2017-07-18 Impact factor: 5.742
Authors: Yasuhiro Oki; Jason R Westin; Francisco Vega; Hubert Chuang; Nathan Fowler; Sattva Neelapu; Fredrick B Hagemeister; Peter McLaughlin; Larry W Kwak; Jorge E Romaguera; Michelle Fanale; Anas Younes; Maria Alma Rodriguez; Robert Z Orlowski; Michael Wang; Souzanne T Ouzounian; Felipe Samaniego; Luis Fayad Journal: Br J Haematol Date: 2013-10-01 Impact factor: 6.998
Authors: Michael J Buege; Anita Kumar; Brianne N Dixon; Laura A Tang; Terry Pak; Jennifer Orozco; Tim J Peterson; Kathryn T Maples Journal: Ann Pharmacother Date: 2020-02-20 Impact factor: 3.154